


In the format provided by the authors and unedited.


Genetic evidence of assortative mating in humans

Matthew R. Robinson, Aaron Kleinman, Mariaelisa Graff, Anna A. E. Vinkhuyzen, David Couper, Michael B. Miller, Wouter J. Peyrot, Abdel Abdellaoui, Brendan Zietsch, Ilja M. Nolte, Jana V. van Vliet-Ostaptchouk, Harold Snieder, The LifeLines Cohort Study, Genetic Investigation of ANthropometric Traits (GIANT) consortium, Sarah Medland, Nicholas G. Martin, Patrik K. E. Magnusson, William G. Iacono, Matt McGue, Kari E. North, Jian Yang & Peter M. Visscher


SUPPLEMENTARY FIGURES




Supplementary Figure 1. Power to test whether the observed correlation among partners is greater than expected in the population for estimated genome-wide sharing of single nucleotide polymorphisms (SNPs). We assume 50,000 independent common SNP markers in the genome and a type-I error rate of 0.05. h^2 is the simulated heritability captured by common loci, and r is the phenotypic correlation. Genome-wide sharing statistic between any two individuals j and l is $\pi_{jl} = \left(\frac{1}{k}\right) \sum_{i=1}^k (w_{ij}w_{il})$ where $w_i = \frac{x_i - 2p_i}{\sqrt{2p_i(1-p_i)}}$ with x_i the SNP dosage score and p_i the frequency of the i^{th} SNP.




Supplementary Figure 2. Approximate summary statistic best linear unbiased genetic predictor (SBLUP). In our simulation study, 5000 SNPs were randomly selected as causal variants and effect sizes were allocated to these markers from a standard normal distribution. For each of 50 replicates, a phenotype was generated for all individuals, a genome-wide association study (GWAS) of the phenotype was conducted in a randomly selected set of 20,000 individuals at 1.2 Million HapMap3 SNPs, the SNP effect estimates were converted to approximate best linear unbiased predictor (SBLUP) SNP effects using a reference set of 10,000 randomly selected individuals, the BLUP SNP effects were used to create an approximate BLUP genetic predictor in 19,000 randomly selected individuals. We compare the SBLUP predictor (blue circles) to a predictor made from directly estimated BLUP SNP effects in an individual-level REML model (BLUP; green circles), and to a predictor made from the GWAS least squares SNP estimates (least squares; grey circles). The left-hand panel shows the slope of a regression where the phenotype is the dependent variable and the genetic predictor is the independent variable. The right-hand panel shows the correlation of the phenotype with the genetic predictor. The SBLUP approach has the same regression slope and correlation with the phenotype as the individual-level BLUP, and has improved prediction accuracy over a genetic predictor made from least squares estimates of the SNP effects.




Supplementary Figure 3. Predicting phenotype of an individual from the genotype of their partner to estimate the degree to which assortative mating creates a genetic correlation at trait-associated loci among partners. We conducted a simulation study using real genotype data from 60,000 unrelated individuals. For each of 50 replicates, a phenotype was generated for all individuals, a genome-wide association study (GWAS) of the phenotype was conducted in a randomly selected set of 20,000 individuals at 1.2 Million HapMap3 SNPs, the SNP effect estimates were converted to approximate best linear unbiased predictor (BLUP) SNP effects using a reference set of 10,000 randomly selected individuals, the BLUP SNP effects were used to create a genetic predictor in 19,000 randomly selected individuals that were assigned to 9500 pairs, and finally we estimated the genetic assortative mating correlation for the phenotype using our framework (see Methods). We simulated three scenarios. In the first scenario (phenotypic assortment), individuals were paired based on their phenotype, with a spousal phenotypic correlation of 0.2. In the second scenario (ancestry assortment), individuals were paired based on their ancestry, defined as an individual's cumulative sum of the first 10 eigenvector values calculated from the SNP data, with a spousal correlation of 0.8. In the third scenario (trait correlated ancestry assortment), individuals were paired on their ancestry with a spousal correlation of 0.8 and the first 10 eigenvectors explained 5% of the phenotypic variance, which creates a genotype-environment correlation for the phenotype. The genetic assortative mating correlation for the phenotype is shown across 50 replicates for each pairing scenario, divided into different analysis approaches depending upon whether population stratification was controlled for in the discovery analysis. In the first scenario (phenotypic assortment), our approach returns the correct simulated value when population stratification is controlled for in the discovery analysis (shown in blue) and is only slightly reduced toward zero when population stratification is not accounted for in the discovery analysis (shown in green). In the second scenario (ancestry assortment) the spouse pair correlation is 0 for the phenotype and we found that the genetic assortative mating correlation for the trait was never significantly different from zero under the extreme scenario of no control for population stratification in the discovery analysis. In the third scenario (trait correlated ancestry assortment) there is genotype-environment correlation for the phenotype and again we found that the genetic assortative mating correlation for the trait was never significantly different from zero under the extreme scenario of no control for population stratification in the discovery analysis. Therefore, our approach is unbiased provided that principal components of the genotypic data capture the stratification that occurs.




Supplementary Figure 4. BLUP properties of the SBLUP predictor. In our simulation study, we altered the lambda parameter across simulations in the approximate summary statistic BLUP (SBLUP) analysis, and then re-estimated the genetic correlation at trait-associated loci. Across all simulations the phenotypic correlation among partners was 0.2. When the genetic predictor has BLUP properties of a regression coefficient of phenotype on predictor of 1, and there is direct assortative mating on the phenotype, then the estimated correlation at trait-associated loci equals the phenotypic correlation. When the genetic predictor does not have BLUP properties then the estimate changes in proportion to the phenotypic correlation multiplied by the slope of the genetic predictor.




Supplementary Figure 5. Simulation study of assortative mating on a correlated trait. We extended our simulation study using real genotype data from 60,000 unrelated individuals, to simulate assortative mating for a correlated trait. For each of 50 replicates, we paired individuals on the basis of an unobserved genetically correlated trait (genetic correlation, r_G , either 0.5 or 0.75, and heritability either 0.5 and 0.8), with a partner correlation, r_P , of either 0.75 or 0.5. We then re-estimated Eq. 7 in each simulation scenario (blue square) for a focal trait that was measured and we compare the estimates gained to their expectation under Eq. 7.10 (grey circles). The phenotypic correlation among partners for the measured focal trait is shown by green diamonds. Error bars give the SD of the estimates across 50 replicates.




Supplementary Figure 6. Association between ancestry, phenotype, and genetic predictors of height and body mass index (BMI) among partners. (a) In the combined sample there is a high correlation at the leading principal components (PCs) of the genetic data among partners because pairing occurs within each study and within ethnicities. (b) Without correction for PCs, a genetic predictor of height and BMI for an individual is correlated with the leading PC values of their partner both positively and negatively. (c) Phenotypically, when height and BMI are converted to a z-score within each cohort, the PCs for which there is a high correlation among partners do not show a consistent directional correlation with either trait. (d) Therefore without correction for PCs, the estimate of the degree to which partners share trait associated loci is underestimated because there is no consistent directional match between ancestry sharing and the correlation between ancestry and trait value. Error bars give the SE of the estimates.



Supplementary Figure 7. SNP heritability of differences among individuals in their partner phenotype. In our simulation study, we estimated the SNP heritability of the simulated phenotype using REML, from which a theoretical expectation of the SNP heritability of differences among individuals in their partner phenotype can be derived (theoretical expectation). This theoretical expectation was then compared to the estimates gained from the analysis of the simulated data. Values shown are the point estimates across the 50 simulation replicates.



Supplementary Figure 8. Predicting phenotype from associations of an individual's phenotype with their partner's genotype. In our simulation study, we estimated the correlation of the simulated phenotype and a BLUP genetic predictor, from which a theoretical expectation can be derived of the correlation of an individual's phenotype with a genetic predictor created from the SNP effects gained in a mixed-linear model association analysis using their partners genotype as a trait (theoretical expectation). This theoretical expectation was then compared to the estimates gained from the analyses of the simulated data. Values shown are the point estimates across the 50 simulation replicates.



Supplementary Figure 9. Correlation of genetic predictors among partners for height (green) and educational attainment (blue) in 7,780 couples from the UK Biobank study, estimated using different subsets of SNP markers. Using summary statistics from recent GWAS studies and the clumping procedure in the software PLINK, we selected subsets of SNPs in linkage equilibrium (LD correlation < 0.01 within 1MB) that were associated with each trait across a wide range of significance thresholds. For each significance threshold, the SNPs selected were used to create a genetic predictor directly from the ordinary least squares estimates of the SNP effects, and we estimated the proportion of phenotypic variance explained and the correlation among partners. The expectation of the correlation in genetic predictors among partners is the product of the phenotypic correlation among partners (0.2 for height and 0.4 for educational attainment) and the phenotypic variance explained by the genetic predictor, and this is given on the x-axis. The y-axis then gives the estimate of the correlation of genetic predictors among partners. Each point represents the expectation and the estimate obtained using a predictor that contains SNPs selected at different clumping thresholds, with the size of the point reflecting the number of SNPs used in the genetic predictor. Error bars show the SE of the estimate.

SUPPLEMENTARY TABLES

Analysis	Cohort	Sample size	Number of SNP Markers
Spousal pair analyses	Composite sample (ARIC, HRS, LL, MCTFR)		
	<i>Atherosclerosis Risk in Communities Study (ARIC)</i>	2,245 pairs	1,171,654
	<i>Health and Retirement Study (HRS)</i>	1,195 pairs	1,337,895
	<i>LifeLines Study (LL)</i>	818 pairs	1,170,052
	<i>Minnesota Center for Twin and Family Research Study (MCTFR)</i>	786 pairs	1,195,036
	Total	5,044 pairs	1,135,785
	Sample from 23andMe research participant cohort	11,908 pairs	1,134,501
	Sample from the UK Biobank	7,780 pairs	1,162,900
Approximate BLUP genetic prediction	Reference SNP marker set from TwinGene study	10,729 individuals	1,121,023
	Ridge regression prediction in individuals from the combined sample (ARIC, HRS, LL, MCTFR) that are not part of, or related to, spousal pairs	18,134 individuals	1,135,785
Simulation study	Unrelated European individuals from Kaiser Permanente study (GERA)	10,729 individuals	1,121,023

Table S1. Cohorts used at each stage of analysis with their sample size and number of imputed HapMap3 SNP markers passing QC.

SUPPLEMENTARY NOTE

Expected genome-wide SNP sharing conditional on phenotypic similarity

Consider a phenotype as $y_j = \sum_{i=1}^k w_{ij} b_i + e_j$, where $w_{ij} = \frac{(x_{ij}-2p_i)}{\sqrt{2p_i(1-p_i)}}$, with x_{ij} the SNP dosage score of the j^{th} individual, b_i the allelic effect of the i^{th} causal variant with allele frequency p_i , and e_j the residual (environmental effect) with y having mean zero and variance 1, and k the number of SNP markers. If $a_j = \sum_{i=1}^k w_{ij} b_i$, then $\sigma_a^2 = \sum_{i=1}^k (b_i^2) = h^2$, with h^2 the heritability of the phenotype.

For genome-wide sharing, the best-case scenario for detection is to consider the causal variants directly and to assume that all causal variants are independent. For any two individuals j and l , the sharing statistic π_{jl} can be considered as a random variable $\pi_{jl} = (\frac{1}{k}) \sum_{i=1}^k (w_{ij} w_{il})$. At the population-level, $\mathbb{E}(w_{ij} w_{il}) = 0$ and $\sigma_{w_{ij} w_{il}}^2 = 1$ and hence $\mathbb{E}(\pi_{jl}) = 0$ and $\sigma_{\pi_{jl}}^2 = 1/k$.

The relationship between phenotypic and genomic sharing is $y_j y_l | \pi_{jl} = h^2 \pi_{jl} + e$, which for a randomly selected pair of individuals in a population $\mathbb{E}(y_j y_l) = 0$ and $\sigma_{y_j y_l}^2 = 1$. Previous work on assortative mating has focussed on the genomic sharing at SNP loci conditional on phenotypic sharing which is $\pi_{jl} | y_j y_l = \mu + \beta y_j y_l + e$, where $\beta = \frac{\sigma(\pi_{jl}, y_j y_l)}{\sigma_{y_j y_l}^2} = h^2 \sigma_{\pi}^2$ and μ is an intercept with $\mathbb{E}(\mu) = 0$.

Hence,

$$\pi_{jl} | y_j y_l = h^2 \sigma_{\pi}^2 y_j y_l + e = \left(\frac{h^2}{k}\right) y_j y_l + e \quad [1]$$

If the phenotypes for the pairs j and l are ascertained as is the case when selecting partners, then we can express the expected value of their product as their phenotypic correlation, $\mathbb{E}(y_j y_l | \text{ascertainment}) = r$, with r the phenotypic correlation.

The expectation of Eq. [1] then becomes:

$$\mathbb{E}(\pi_{jl} | y_j y_l) = r h^2 / k, \quad [2]$$

with variance:

$$\sigma_{\pi_{jl} | y_j y_l}^2 = \sigma_{\pi_{jl}}^2 - \sigma_{(h^2/k) y_j y_l}^2 = \left(\frac{1}{k}\right) - \left((h^2/k) y_j y_l\right)^2 = \left(\frac{1}{k}\right) \left(1 - \frac{h^4}{k}\right)$$

Hence for detection using a statistical test, the non-centrality parameter (NCP) of a test for mean sharing among N selected pairs against a population-level value of zero is:

$$NCP = \frac{N(r^2 h^4 / k^2)}{\left(\frac{1}{k}\right) \left(1 - \frac{h^4}{k}\right)} = \frac{N r^2 h^4}{k - h^4} \quad [3]$$

If the heritability is ~ 1 and if pairs are selected with identical phenotypes ($r = 1$) then $NCP = N/(k-1)$, and thus the power depends on the number of causal variants relative to the sample size (N pairs). Evidence suggests that for a complex phenotype like height, $k \gg 1000$ and thus even in the scenario where all causal variants are known and pairs

are selected with identical phenotypes, ~8000 pairs would be required to detect a significant deviation from the null at $p < 0.05$ if we assume $k = 2000$.

In reality, the phenotypic correlation among partners for height is $r \sim 0.2$, the h^2 captured by SNP loci ~ 0.5 , and k is the effective number of common independent markers in the genome $\sim 50,000^1$. Placing these numbers into Eq. [3] reveals that 7 million couples would be required in order to detect a deviation from expectation in genome-wide sharing. Power calculations from Eq. [3] are presented in Supplementary Figure 1 assuming a type-I error rate of 0.05.

These results demonstrate that very large sample size is required to detect whether couples share more SNP marker alleles than randomly selected pairs of individuals from the population and thus we devised a novel approach to estimating the genetic basis of phenotypic assortment.

Genetic (co)variance of phenotype and mate choice in related individuals

A recent study³², presents a variance components approach for examining the genetic basis of assortative mating for a phenotype. They present a bivariate linear mixed effects model, where the first phenotype is the phenotype of the individual and the second is the phenotype of their chosen partner. In this model, the phenotypic (co)variance is partitioned into two components, genetic (co)variance using a relationship matrix estimated from SNP data, and residual (co)variance. The study uses data that is a mixture of unrelated and related individuals and as a result, like all family designs, it does not allow for a complete separation of genetic effects from common environment effects. This is because genetic and common environment effects, while being uncorrelated, may be confounded as close relatives share both genes and their environment to a greater extent than to other individuals.

Consider a phenotype as $y_j = a_j + c_j + e_j$, where a_j is the additive genetic value for the j^{th} individual, c_j are cultural or common environment effects that are shared among close relatives who come from the same family background, and e_j the residual (environmental effect). We assume $\sigma(c, e) = \sigma(a, e) = 0$ and a phenotypic variance of 1, giving $\sigma_p^2 = h^2 + c^2 + e^2$, with h^2 the heritability. One approach to estimating the heritability of a trait is to determine the covariance amongst full siblings, with $h^2 = 2\sigma(y_j, y_k)$, where y_j and y_k are the phenotypes of sibling j and k respectively.

The covariance between full siblings is $\sigma(y_j, y_k) = \sigma(a_j, a_k) + \sigma(c_j, c_k) + \sigma(e_j, e_k)$. We can then consider the covariance between a sibling and their partner which is $\sigma(y_j, y_{s_j}) = \sigma(a_j, a_{s_j}) + \sigma(c_j, c_{s_j}) + \sigma(e_j, e_{s_j})$, and the covariance between the partners of the full siblings is then $\sigma(y_{s_j}, y_{s_k}) = \sigma(a_{s_j}, a_{s_k}) + \sigma(c_{s_j}, c_{s_k}) + \sigma(e_{s_j}, e_{s_k})$. The expected value of the estimate of heritability of mate choice from this full sibling design is $h_{choice}^2 = 2\sigma(y_{s_j}, y_{s_k})$.

The covariance terms depend on the assumptions as to the mechanism of assortment and the assumptions on how the shared / common environment effects, c , covary between the full siblings and their spouses. In an extreme case, where all mate assortment is due to shared common environment effects and these are fully shared between full siblings then, $\sigma(y_1, y_2) = \frac{1}{2}h^2 + c^2$ and $\sigma(y_j, y_{s_j}) = r(c_j, c_{s_j})c^2 = m$, with the correlation in the non-genetic shared environment effects among partners and m is the phenotypic correlation among partners. In this scenario, the only covariance between the spouses of the full siblings is through sharing of family background, with $\sigma(y_{s_j}, y_{s_k}) = \sigma(c_{s_j}, c_{s_k}) = r(c_{s_j}, c_{s_k})c^2 = r(c_j, c_{s_j})r(c_j, c_k)r(c_k, c_{s_k})c^2 =$

$r(c_j, c_{s_j})^2 c^2 = r(c_j, c_{s_j}) m$. With these assumptions, the expected value of the estimate of heritability of realized mate choice is $h_{choice}^2 = 2\sigma(y_{s_j}, y_{s_k}) = 2r(c_j, c_{s_j}) m$.

If we assume values of $r(c_j, c_{s_j})$ from 0.1 to 0.5 and c^2 from 0.1 to 0.2 then h_{choice}^2 ranges from 0.2% to 10% and m ranges from 0.01 to 0.1. For height, m has been characterized in the human population as ~ 0.2 , common environment effects of ~ 0.1 have been reported⁵⁴, there is evidence for pairing on family background with correlation, $r(c_{s_1}, c_{s_2}) = 0.5$ ⁵⁴ and a recent study finds $h_{choice}^2 \sim 0.04$ ³², meaning that the model described here is not consistent with current findings for height. However, the contribution of shared environment to phenotypic variance, and the degree to which individuals assort based on environmental effects such as family similarity will vary depending upon the phenotype. It is clear that under this model and these assumptions, covariance of the phenotypes of the spouses of relatives can contain an environmental component. Therefore, when using data on relatives mate choice based on family background can make it appear as though attraction to a mate of similar phenotype can be explained by a person's genotype with a high 'genetic' correlation between the phenotype and choice of the phenotype.

In this study, we use unrelated individuals when estimating h_{choice}^2 . Although the estimates of h_{choice}^2 for unrelated individuals will be unbiased by shared environment effects, partitioning the phenotypic covariance of spousal pairs into genetic and environmental components in a bivariate mixed model will likely always yield a significant estimate of both genetic and environmental covariance, even under direct mate choice. Therefore, conclusions as to the relative contributions of different mechanisms are difficult and hence we take the approach of predicting the phenotype of an individual from the genotype of their partner, enabling a direct comparison of the degree to which phenotypic assortment among partners creates a correlation at trait-associated loci, that is free of environmental confounding.

Correlation of effect size estimates made using the same individuals

Another approach to assessing whether the genetic basis of a phenotype and mate choice of phenotype are the same, is to estimate the correlation between (i) GWAS summary statistics for the trait, and (ii) GWAS summary statistics when the partner's phenotype is treated as the choice of an individual. However, when these two association studies are conducted on identical samples in the same population (in (i) and (ii) the same genetic markers are used), this analysis can result in a significant correlation in the estimated regression coefficients even when no genetic correlation exists between the trait and choice of the trait.

Consider a scenario where two phenotypes measured on the same individuals, $y1_j = \sum_{i=1}^k w_{ij} b1_i + e1_j$, and $y2_j = \sum_{i=1}^k w_{ij} b2_i + e2_j$, the allelic effects $b1$ and $b2$ arise from a multivariate normal distribution with $\sigma_{b1}^2 = h_1^2/m$, $\sigma_{b2}^2 = h_2^2/m$ and $\sigma_{b1,b2} = 0$, giving a genetic correlation between the two phenotypes of 0. The environmental effects $e1$ and $e2$ also arise from a multivariate normal distribution with $\sigma_{e1}^2 = 1 - h_1^2$, $\sigma_{e2}^2 = 1 - h_2^2$ and $\sigma_{e1,e2}$ the environmental covariance, which will be high when the phenotype is measured on identical individuals. For example, it is likely that family background is correlated with the environment experienced during development, the developmental environment influences variation of many phenotypes, and family background influences mate choice, which together create an environmental covariance between an individual's trait value and their choice of partner.

Following⁵⁵, if b_{1_i} and b_{2_i} are estimated in linear regressions on identical samples then the covariance in the estimated effects is $cov(\hat{b}_{1_i}, \hat{b}_{2_i}) = m \sqrt{\frac{\sigma_{y_1}^2 \sigma_{y_2}^2}{N}}$, which reflects the phenotypic correlation m , a correlation that may be both genetic and environmental. To demonstrate this we use the same simulation approach described above, to generate two phenotypes ($h_1^2 = 0.7$; $h_2^2 = 0.04$) with a genetic correlation of zero and an environmental correlation of 0.2. Across 50 simulation replicates, the estimated SNP effect sizes were correlated at 0.203 (0.01 SD). Therefore in this study, we took the approach of conducting the discovery and then prediction in independent samples to avoid the potential for environmentally induced covariance in SNP effect sizes estimates.

SUPPLEMENTARY METHODS

Approximate BLUP genetic predictor (SBLUP)

Genome-wide association studies (GWAS) analyze one SNP at a time using the model $\mathbf{y} = \mathbf{X}_i\beta_i + \mathbf{e}$, where \mathbf{y} is a $N \times 1$ vector of the phenotype, \mathbf{X}_i is a $N \times 1$ vector of genotypes for each SNP $i = 1, \dots, k$ (coded as 0, 1, or 2 defining the number of reference alleles), with k the number of SNP markers, and \mathbf{e} is an $N \times 1$ vector of residuals. The computed least-squares estimates of the effect size, $\hat{\beta}_i$, of this model can be written as $\text{diag}(\mathbf{X}^T\mathbf{X})\hat{\boldsymbol{\beta}} = \mathbf{X}^T\mathbf{y}$.

We re-estimated these SNP estimates in a random effects model that converts the least squares estimates, $\hat{\beta}$, into approximate best linear unbiased predictors (BLUP). The motivation behind this is that prediction power is maximized and the genetic predictor gained has BLUP properties which include of a regression slope of 1 on the phenotype^{2,3}. To obtain the BLUP estimates of SNP effects, the effects of all SNPs are fitted jointly in a random effect model as $\mathbf{y} = \mathbf{X}\mathbf{b} + \mathbf{e}$ with $\mathbf{b} \sim N(0, \sigma_b^2)$ and $\mathbf{e} \sim N(\mathbf{0}, \sigma_e^2)$, and the BLUP solution is $\hat{\mathbf{b}} = (\mathbf{X}^T\mathbf{X} + \mathbf{I}\lambda)^{-1}\mathbf{X}^T\mathbf{y}$, with $\lambda = \sigma_e^2/\sigma_b^2$. Although \mathbf{X} and \mathbf{y} in the discovery set are not available when using summary statistics, we can approximate the covariance matrix of SNP genotypes, $\mathbf{X}^T\mathbf{X}$, by that from a reference cohort, $\mathbf{W}^T\mathbf{W}$, that is independent from the prediction population as $\mathbf{X}^T\mathbf{X} \approx \frac{\mathbf{W}^T\mathbf{W}n_d}{n_r} = \mathbf{B}$ with n_d and n_r being the samples sizes of the discovery set and reference sample, respectively. This assumes that the allele frequencies and linkage disequilibrium (LD) between SNPs in the discovery set are similar to those in a reference sample. We can also approximate $\mathbf{X}^T\mathbf{y} = \text{diag}(\mathbf{B})\hat{\boldsymbol{\beta}}$. We therefore have $\hat{\mathbf{b}} = (\mathbf{B} + \mathbf{I}\lambda)^{-1}\text{diag}(\mathbf{B})\hat{\boldsymbol{\beta}}$.

Since the random effect model assumes every SNP has an effect on the trait, the proportion of phenotypic variance explained by all SNPs is $h_g^2 = k\sigma_b^2/\sigma_p^2$ with k being the total number of SNPs used in the analysis and σ_p^2 being the phenotypic variance (which is ~ 1 if the discovery GWAS was based on standardised phenotype). We then have $\lambda = k[1 - h_g^2]/h_g^2$.

For each individual, the BLUP SNP effects can be used to create a genetic predictor as $\hat{g} = \sum_{i=1}^k x_i \hat{b}_i$, where x_i the number of SNP minor alleles at SNP i (again coded 0, 1, or 2), \hat{b}_i the BLUP effects estimate at SNP i , which is then summed over k SNPs to give a $N \times 1$ vector of predicted genetic effects, \hat{g} . This predictor has the expected property $\sigma(g, \hat{g}) = \sigma_g^2$ where g is the genetic predictor gained if the true SNP effects were known. This follows a recent study⁴ and is implemented within the software package GCTA⁵ under the term SBLUP (--cojo-sblup).

We used the meta-analysis SNP effect size estimates and gained BLUP approximations of the SNP effects using the TwinGene cohort (Supplementary Table 1) as a reference. Our theory and empirical analyses outlined below rely on the assumption that the slope of the regression of the BLUP predictor on the phenotype is ~ 1 . We therefore conducted a ridge regression to find the value of λ that gives a predictor with these BLUP properties of a regression slope of 1 on the phenotype. We selected individuals from the cohorts listed in Supplementary Table 1 that had genotypic and phenotypic data, but were not part of a spouse pair or related to the spouse pairs, and we devised an algorithm to grid search the value of lambda that gave a regression slope of 1 within this data. Data access restrictions prevented a ridge regression tailored specifically to the 23andMe data.

Predicting the phenotype of an individual from the genotype of their partner

To estimate the degree to which assortative mating creates a genetic correlation at trait-associated loci, we first determined the relationship between the genetic predictor of males and the phenotype of their female partner, and vice versa as:

$$\begin{aligned} y_m &= \mu_m + \hat{g}_{p_f} + u_m + e_m, \\ y_f &= \mu_f + \hat{g}_{p_m} + u_f + e_f \end{aligned} \quad [4]$$

where u is a $N \times 1$ vector of the total genetic effects of the individuals, with $u = N(0, \mathbf{A}\sigma_G^2)$, \mathbf{A} is the genetic relationship matrix (GRM) between either males (when estimating u_m), or females (when estimating u_f) with its j th element being $A_{jl} = \frac{1}{N} \sum_{i=1}^N \frac{(x_{ij}-2p_i)(x_{il}-2p_i)}{2p_i(1-p_i)}$ where p_i is the frequency of the minor allele of the imputed HapMap3 common SNP i and x is the SNP genotype (best guess for the combined cohort and rounded imputed diploid dosage for the 23andMe cohort). The GRM accounts for population stratification in the phenotype, as it is equivalent to fitting all the principal components within the model. Eq. [4] was estimated using the GREML function in GCTA v1.25.

The expectation of the regression coefficient from a linear regression of the phenotype of males on the genetic predictor of their female partners and vice versa can be derived under different types of assortative mating. Under direct assortment on a quantitative trait in Eq. [4]:

$$\mathbb{E}[\sigma(y_m, \hat{g}_f)] = b_{y_m, y_f} \sigma(y_f, \hat{g}_f), \quad \text{with } b_{y_m, y_f} = \frac{\sigma(y_m, y_f)}{\sigma^2(y_f)} \quad [5]$$

If y_m and y_f are standardized to a z-score with mean = 0 and variance = 1 then:

$$\mathbb{E}[b_{y_m, y_f}] = r(y_m, y_f) \quad [6]$$

where r is the correlation. Under the BLUP assumptions of $\sigma(g, \hat{g}) = \sigma_{\hat{g}}^2$ then:

$$\mathbb{E}[\sigma(y_f, \hat{g}_f)] = \sigma(g_f, \hat{g}_f) = \sigma_{\hat{g}_f}^2 \quad [7]$$

and in Eq. [4] the slope of the regression of y_m on \hat{g}_f is:

$$\mathbb{E}[b_{y_m, \hat{g}_f}] = \frac{\sigma(y_m, \hat{g}_f)}{\sigma_{\hat{g}_f}^2} = \frac{r(y_m, y_f)\sigma(y_f, \hat{g}_f)}{\sigma(y_f, \hat{g}_f)} = r(y_1, y_2) \quad [8]$$

An alternative scenario is where assortment occurs on a trait that is correlated to the observed trait. If y is the trait upon which assortment occurs, but z is the trait that is measured then the observed correlation among couples for trait z will be:

$$r(z_1, z_2) = r(y, z)^2 r(y_1, y_2) \quad [9]$$

If we assume both traits have unit variance, we can consider the phenotypic regression of z on y :

$$z = r(y, z)y + e \quad [10]$$

and the genetic regression of z on y assuming that the true genetic value is known:

$$g_z = (r(g_y, g_z)h_z/h_y)g_y + e \quad [11]$$

with h_z^2 and h_y^2 the heritability of trait z and y respectively. Then the expectation of the covariance of trait z in males and the genetic value of their female partners is:

$$\begin{aligned} \mathbb{E}[\sigma(z_m, g_{z_f})] &= \sigma(r(y, z)y_m, (r(g_y, g_z)h_z/h_y)g_y) \\ &= r(y, z) r(g_y, g_z)h_z/h_y \sigma(y_m, g_{y_f}) \end{aligned}$$

$$\begin{aligned}
 &= r(y, z) r(g_y, g_z) h_z / h_y (r(y_1, y_2) h_y^2) \\
 &= r(y, z) r(y_1, y_2) r(g_y, g_z) h_z h_y
 \end{aligned}
 \tag{12}$$

So then the regression of trait z in males on the genetic value of their female partners, g_{zf} , is:

$$\mathbb{E}[b_{z_m g_{zf}}] = \frac{r(y, z) r(y_1, y_2) r(g_y, g_z) h_z h_y}{h_z^2} = r(y, z) r(y_1, y_2) r(g_y, g_z) h_y / h_z
 \tag{13}$$

If both traits are the same, $y = z$, then $r(y, z) = 1$, $r(g_y, g_z) h_y / h_z = 1$ and thus Eq. [13] reverts to Eq. [8]. Using Eq. [9] the ratio, d , of the expectation under assortment on a correlated trait, relative to the expectation under direct assortment is:

$$\mathbb{E}[d] = \frac{r(y, z) r(y_1, y_2) r(g_y, g_z) h_y}{r(z_1, z_2) h_z} = \frac{r(g_y, g_z) h_y}{r(y, z) h_z}
 \tag{14}$$

meaning that under assortment on a correlated trait the estimate from Eq. [4] can either be higher or lower than the expectation given by Eq. [8] depending upon (i) the magnitude of the genetic correlation as compared to the phenotypic correlation of z and y , and (ii) the heritability of y as compared to that of z .

Under both direct assortment on a phenotype and assortment on correlated traits, a correlation among partners at trait associated loci is expected, with Eq. [8] providing the expectation under direct assortment, and Eq. [13] providing the expectation under secondary assortment. Therefore, our approach provides an estimate of the correlation among couples at trait associated loci but cannot differentiate between direct assortment on a phenotype and assortment on a genetically correlated trait. However, our approach does differentiate between assortative mating based on selection of phenotypic characteristics and assortative mating based on shared social/environmental factors, because under only social/environmental homogamy we would not expect an association between genetic predictors of phenotype within the mixed effect model of Eq. [4] as it accounts for population stratification, by both regressing PCs from the genetic predictor, and by fitting a relationship matrix estimated from the SNP markers.

We estimated Eq. [4] in the combined set of data, and we then repeated the estimation in the 23andMe and then the UK Biobank data. The estimates gained were adjusted by the regression coefficient gained from regressing the phenotypic values onto the adjusted genetic predictors. This was done to ensure that the genetic predictor has the expected BLUP properties. We then compared our estimates from Eq. [4] to the phenotypic correlation between partners in z -scores of their phenotype.

Common SNP heritability of realized mate choice

We estimated the heritability associated with common SNPs (h_{SNP}^2) for realized mate choice of height and body mass index as:

$$\begin{aligned}
 \mathbf{y}_m &= \mu_m + \mathbf{Z}\boldsymbol{\beta}_m + \mathbf{u}_f + \mathbf{e}_m, \\
 \mathbf{y}_f &= \mu_f + \mathbf{Z}\boldsymbol{\beta}_f + \mathbf{u}_m + \mathbf{e}_f
 \end{aligned}
 \tag{15}$$

with notation the same as above. Eq. [15] controls for population stratification by fitting the effects of the first 20 principal components estimated within the 23andMe data before then estimating the effects $\mathbf{u} = N(0, \mathbf{A}\sigma_G^2)$. We selected Hapmap3 common SNPs from the best-guess imputed SNP data to estimate \mathbf{A} and thus σ_G^2 is the variance explained by those SNPs. Eq. [15] was estimated using the GREML function in GCTA v 1.25.

The expectation of h_{SNP}^2 estimated in Eq. [15] can be derived if we consider Eq. [15] as the regression

$$\mathbf{y}_{m_j}\mathbf{y}_{m_l} = \mu + \beta\mathbf{p}_{i_{f_j},f_l} + \mathbf{e}, \quad [16]$$

with $\mathbf{y}_{m_1}\mathbf{y}_{m_2}$ an $N \times 1$ vector of the phenotypes of the males of the j^{th} couple multiplied together, $\mathbf{p}_{i_{f_j},f_l}$ an $N \times 1$ vector the genetic relationship between the females of the j^{th} couple taken from \mathbf{A} , and β is the regression coefficient.

The expectation of β can be derived by first considering the regression

$$\mathbf{y}_{m_j}\mathbf{y}_{m_l} = \mu + \beta_1(\mathbf{y}_{f_j}\mathbf{y}_{f_l}) + \mathbf{e}, \quad [17]$$

with $\mathbf{y}_{f_j}\mathbf{y}_{f_l}$ an $N \times 1$ vector of the phenotypes of the females of the j^{th} couple multiplied together.

$$\mathbb{E}[\beta_1] = \frac{\sigma(\mathbf{y}_{m_j}\mathbf{y}_{m_l}, \mathbf{y}_{f_j}\mathbf{y}_{f_l})}{\sigma^2\mathbf{y}_{f_j}\mathbf{y}_{f_l}} = \sigma(\mathbf{y}_{m_j}\mathbf{y}_{m_l}\mathbf{y}_{f_j}\mathbf{y}_{f_l}), \quad [18]$$

when all phenotypes are standardised to z-score where $y = N(0, 1)$. Then:

$$\begin{aligned} \sigma(\mathbf{y}_{m_j}\mathbf{y}_{m_l}\mathbf{y}_{f_j}\mathbf{y}_{f_l}) &= \mathbb{E}[\mathbf{y}_{m_j}\mathbf{y}_{m_l}\mathbf{y}_{f_j}\mathbf{y}_{f_l}] - \mathbb{E}[\mathbf{y}_{m_j}\mathbf{y}_{m_l}]\mathbb{E}[\mathbf{y}_{f_j}\mathbf{y}_{f_l}] \\ &= \mathbb{E}[\mathbf{y}_{m_j}\mathbf{y}_{f_j}]\mathbb{E}[\mathbf{y}_{m_l}\mathbf{y}_{f_l}], \end{aligned} \quad [19]$$

and thus we have $\mathbb{E}[\beta_1] = r(\mathbf{y}_m, \mathbf{y}_f)^2$.

Hence, we can then write Eq. [16] as:

$$\beta_1\mathbf{y}_{f_j}\mathbf{y}_{f_l} = \mu + \beta_2\mathbf{p}_{i_{f_j},f_l} + \mathbf{e}, \quad [20]$$

Thus, as the regression of $\mathbf{y}_{f_j}\mathbf{y}_{f_l}$ on $\mathbf{p}_{i_{f_j},f_l}$ provides an estimate of h_{SNP}^2 ^{6,7} then the expectation of β is:

$$\mathbb{E}[\beta] = h_{SNP}^2 r(\mathbf{y}_m, \mathbf{y}_f)^2 \quad [21]$$

Under the assumption of $h_{SNP}^2 \sim 0.5$ for height and ~ 0.2 BMI, and a phenotypic correlation among partners of $\sim 0.3^{8-10}$, our expectation in Eq. [21] is ~ 0.05 for height and ~ 0.018 for BMI. With $N \sim 10,000$ the standard error of these estimates will be ~ 0.04 and thus we are only interested in determining the magnitude of the point estimate rather than assessing whether the estimate is significantly greater than zero. If the estimates conform to the expectation, then this provides further evidence for a correlation at trait associated loci among couples.

Mixed linear model association analysis of realized mate choice

To identify the genomic regions associated with realized mate choice and test for a single genetic basis of the trait and mate choice, which implies direct assortment on phenotype, we conducted a mixed linear model association analysis¹¹ as:

$$\begin{aligned} \mathbf{y}_m &= \mu_m + \mathbf{X}_{f_i}\beta_i + \mathbf{u}_m + \mathbf{e}_m, \\ \mathbf{y}_f &= \mu_f + \mathbf{X}_{m_i}\beta_i + \mathbf{u}_f + \mathbf{e}_f \end{aligned} \quad [22]$$

with notation the same as above, where β_i is the regression coefficient, \mathbf{X}_{m_i} and \mathbf{X}_{f_i} is a $N \times 1$ vector of genotypes for each SNP $i = 1, \dots, k$ (coded as 0, 1, or 2 defining the number of reference alleles), for males and females respectively, and \mathbf{u}_m and \mathbf{u}_f are the polygenic effect (random effect) for males and females respectively, and \mathbf{e} is the

residual. We selected HapMap3 common SNPs (MAF ≥ 0.01) from the best-guess imputed SNP data in Eq. [22] as we did for Eq. [4] and [15]. Eq. [22] was estimated using the MLMA function in GCTA v1.25.

The variance explained by a SNP for a phenotype $y = N(0, 1)$, has the expectation $\mathbb{E}[h_{SNP_k}^2] = 2p(1 - p)\hat{\beta}_i^2$ and thus the expectation of the phenotypic variance explained by a SNP in Eq. [22] is $\mathbb{E}[h_{SNP_k}^2] = 2p(1 - p)\hat{\beta}_i^2 r(y_m, y_f)^2$. For height, genome-wide significant SNPs cumulatively account for $\sim 16\%$ of the phenotypic variance, and thus the expectation is that they should cumulatively account for $\sim 1.4\%$ of the phenotypic variance when using $\hat{\beta}_i$ from Eq. [22]. For BMI, the expectation is only $\sim 0.6\%$ and data sharing restrictions of 23andMe prohibited this analysis in their dataset. Therefore, in this section we only focus on height.

We used the $\hat{\beta}_i$ from Eq. [22] and gained BLUP approximations of the SNP effects using the TwinGene cohort (Supplementary Table 1) as a reference. We used these approximate BLUP SNP effects to create a genetic predictor $\hat{g} = \sum_{i=1}^k x_i \hat{\beta}_i$ for each trait within an independent prediction cohort. We used the individuals from the combined cohorts that had genotypic and phenotypic data, but were not part of a spouse pair or related to the spousal pairs. We estimated principal components (PCs) of the HapMap 3 best-guess imputed SNPs in the prediction cohort. We selected the top 20 PCs to create a $N \times P$ matrix \mathbf{Z} , of eigenvectors across the P selected PCs. For each trait, we then regressed the estimated genetic predictor onto the eigenvectors as $\hat{g} = \mu + \mathbf{Z}\boldsymbol{\beta} + \mathbf{e}$ where μ is the mean and $\boldsymbol{\beta}$ is a $P \times 1$ vector of the regression coefficients, and \mathbf{e} is the residual error. We then adjusted the predictor of each trait as $\hat{g}_p = \hat{g} - \mathbf{Z}\hat{\boldsymbol{\beta}}$. For each trait, we then regressed the phenotypic values onto the adjusted genetic predictor as $y = \mu + \hat{g}_p + \mathbf{e}$ to determine whether phenotypic variance in the prediction set can be explained by a genetic predictor created using $\hat{\beta}_i$ from Eq. [22].

Simulation study

To support our results we conducted a simulation study using real genotype data. We used SNP data from the Kaiser Permanente study (GERA cohort, Supplementary Table 1), where we conducted identical imputation and QC steps described above to select autosomal HapMap3 loci. We selected 60,000 individuals of European ancestry.

We conducted 50 simulation replicates. In each simulation replicate, we:

1. Randomly selected 5000 SNPs that were in approximate linkage equilibrium (LD $r^2 < 0.05$).
2. Simulated a phenotype across all individuals from these loci as: $y_j = \sum_{i=1}^k w_{ij} b_i + e_j$, where $w_{ij} = \frac{(x_{ij} - 2p_i)}{\sqrt{2p_i(1-p_i)}}$, with b_i the allelic effect of the i^{th} causal variant and e_j the residual (environmental effect). b_i was simulated from $N(0,1)$ and e_j was simulated from $N\left(0, \left[\sigma_{\sum_{i=1}^k w_{ij} b_i}^2 \times (1/h^2 - 1)\right]\right)$, where h^2 is the heritability of the trait which we set as 0.5.
3. Estimated the effects of each HapMap3 locus in 20,000 randomly selected individuals in a GWAS, controlling for the first 10 PCs that were estimated in the discovery sample.
4. Gained BLUP approximations of the SNP effects, using a randomly selected set of 10,000 reference individuals.
5. Randomly selected 20,000 individuals and paired them on the basis of their phenotypic values. To do this, we used the phenotypic values of the first half of the sample, and created a new linear variable that was correlated with the

phenotype at $r = 0.2$. We then (i) ordered the first half of the sample based on the new linear variable; (ii) ordered the second half of the sample based on their phenotypic values; (iii) paired the ordered first and second half of the samples. This creates pairs of individuals that are phenotypically assorted with a partner correlation of $r = 0.2$.

6. Estimated Eq. [7.1], [8.1] and [9.1] in the 10,000 pairs of individuals and compared these to our theoretical predictions given $r = 0.2$ among partner phenotypes and $h^2 = 0.5$ for the trait.

Second, we then repeated another 50 simulation replicates, but we did not control for population stratification in the GWAS in step 3.

Third, we then repeated another 50 simulation replicates, where we did not control for population stratification in the GWAS in step 3, and the pairing in step 5 was based upon the cumulative value of the first 10 principal components and not on the phenotype with a spousal pair correlation of $r = 0.8$.

Fourth, after creating the phenotype, y , in step 2 above, we created an association between y and the first 10 principal components so that the first 10 PCs explained ~20% of the phenotypic variance. The pairing in step 5 was based upon the cumulative value of the first 10 principal components and not on the phenotype with a spousal pair correlation of $r = 0.8$. As the first 10 PCs influence the phenotype, this results in a spousal correlation for the phenotype that is due to cultural homogamy rather than assortative mating. Therefore, this final set of simulations tests whether our approach can differentiate cultural homogamy, as captured by principal components of the genetic data, from assortative mating.

Finally, we extended our simulations to support our results under assortative mating for a correlated trait (Eq. 7.6 to 7.11), where assortment occurs for an unobserved trait that is genetically correlated to a trait that is measured. We repeated step 5 above, but we paired individuals on the basis of the 'unobserved' genetically correlated trait (genetic correlation either 0.5 or 0.75, and heritability either 0.5 and 0.8), with a partner correlation of either 0.75 or 0.5. We then re-estimated Eq. 7.1 for the focal measured trait across 50 replicates in each of 8 simulation scenarios and we compare the estimates gained to their expectation under Eq. 7.10.

Web resources

We used the following programs and documentation:

UK Biobank documentation

http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UKBiobank_genotyping_QC_documentation-web.pdf

http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/imputation_documentation_May2015.pdf

R 3.2.3 <https://www.r-project.org/>

GCTA <http://cnsgenomics.com/software/gcta/>

HapMap3 <ftp://ftp.ncbi.nlm.nih.gov/hapmap/>

Imputation <https://github.com/CNSGenomics/impute-pipe>.

HAPI-UR <https://code.google.com/p/hapi-ur/>

Impute2 https://mathgen.stats.ox.ac.uk/impute/impute_v2.html

Plink1.9 <https://www.cog-genomics.org/plink2>

BEAGLE <https://faculty.washington.edu/browning/beagle/b3.html>

Minimac <http://genome.sph.umich.edu/wiki/Minimac>

SUPPLEMENTARY REFERENCES

1. Yang, J. *et al.* Genomic inflation factors under polygenic inheritance. *Eur. J. Hum. Genet.* **19**, 807–12 (2011).
2. de Los Campos, G., Vazquez, A. I., Fernando, R., Klimentidis, Y. C. & Sorensen, D. Prediction of complex human traits using the genomic best linear unbiased predictor. *PLoS Genet.* **9**, e1003608 (2013).
3. Goddard, M. E., Wray, N. R., Verbyla, K. & Visscher, P. M. Estimating Effects and Making Predictions from Genome-Wide Marker Data. *Stat. Sci.* **24**, 517–529 (2009).
4. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–375 (2012).
5. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
6. Haseman, J. K. & Elston, R. C. The investigation of linkage between a quantitative trait and a marker locus. *Behav. Genet.* **2**, 3–19 (1972).
7. Visscher, P. M. *et al.* Statistical Power to Detect Genetic (Co)Variance of Complex Traits Using SNP Data in Unrelated Samples. *PLoS Genet.* **10**, e1004269 (2014).
8. Silventoinen, K., Kaprio, J., Lahelma, E., Viken, R. J. & Rose, R. J. Assortative mating by body height and BMI: Finnish twins and their spouses. *Am. J. Hum. Biol.* **15**, 620–7 (2003).
9. Wood, A. R. *et al.* Defining the role of common variation in the genomic and biological architecture of adult human height. *Nat. Genet.* **46**, 1173–86 (2014).
10. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
11. Yang, J., Zaitlen, N. A., Goddard, M. E., Visscher, P. M. & Price, A. L. Advantages and pitfalls in the application of mixed-model association methods. *Nat. Genet.* **46**, 100–6 (2014).

Behrooz Z Alizadeh (1), H Marike Boezen (1), Lude Franke (2), Pim van der Harst (3), Gerjan Navis (4), Marianne Rots (5), Harold Snieder (1), Morris Swertz (2), Bruce HR Wolffenbuttel (6), Cisca Wijmenga (2)

(1) *Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands*

(2) *Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands*

(3) *Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands*

(4) *Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands*

(5) *Department of Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands*

(6) *Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands*

Goncalo R Abecasis¹; Devin Absher²; Helene Alavere³; Eva Albrecht⁴; Hana Lango Allen⁵; Peter Almgren⁶; Najaf Amin⁷; Philippe Amouyel⁸; Denise Anderson^{9,10}; Alice M Arnold^{11,12}; Dominique Arveiler¹³; Thor Aspelund^{14,15}; Folkert W Asselbergs¹⁶; Themistocles L Assimes¹⁷; Mustafa Atalay¹⁸; Antony P Attwood^{19,20,21}; Larry D Atwood²²; Stephan JL Bakker²³; Beverley Balkau^{24,25}; Anthony J Balmforth²⁶; Cristina Barlassina²⁷; Inês Barroso^{19,28}; Hanneke Basart²⁹; Sabrina Bauer³⁰; Jacques S Beckmann^{31,32}; John P Beilby^{33,34,35,36}; Amanda J Bennett³⁷; Yoav Ben-Shlomo³⁸; Richard N Bergman³⁹; Sven Bergmann^{31,40}; Sonja I Berndt⁴¹; Reiner Biffar⁴²; Anna Maria Di Blasio⁴³; Bernhard O Boehm⁴⁴; Michael Boehnke¹; Heiner Boeing⁴⁵; Eric Boerwinkle⁴⁶; Jennifer L Bolton⁴⁷; Amélie Bonnefond⁴⁸; Lori L Bonnycastle^{49,50}; Dorret I Boomsma⁵¹; Ingrid B Borecki^{52,53}; Stefan R Bornstein^{54,55}; Nabila Bouatia-Naji^{56,57}; Gabrielle Boucher⁵⁸; Jennifer L Bragg-Gresham¹; Paolo Brambilla⁵⁹; Marcel Bruinenberg⁶⁰; Thomas A Buchanan^{39,61}; Christa Buechler³⁰; Gemma Cadby^{62,63}; Harry Campbell⁴⁷; Mark J Caulfield⁶⁴; Christine Cavalcanti-Proença^{56,57}; Giancarlo Cesana⁶⁵; Stephen J Chanock⁴¹; Daniel I Chasman^{66,67}; Yii-Der Ida Chen^{68,69}; Peter S Chines^{49,50}; Deborah J Clegg⁷⁰; Lachlan Coin⁷¹; Francis S Collins^{49,50}; John M Connell^{72,73}; William Cookson⁷⁴; Matthew N Cooper⁷⁵; Damien C Croteau-Chonka⁷⁶; L Adrienne Cupples⁷⁷; Daniele Cusi^{78,79}; Felix R Day⁸⁰; Ian NM Day⁸¹; George V Dedoussis⁸²; Mariano Del^{83,84}; Panos Deloukas¹⁹; Emmanouil T Dermitzakis⁸⁵; Antigone S Dimas^{85,86,87}; Maria Dimitriou⁸²; Anna L Dixon⁸⁸; Marcus Dörr⁸⁹; Cornelia M van Duijn^{7,90,91}; Shah Ebrahim^{92,93}; Sarah Edkins¹⁹; Gudny Eiriksdottir¹⁴; Kristina Eisinger³⁰; Niina Eklund^{94,95}; Paul Elliott^{71,96}; Raimund Erbel⁹⁷; Jeanette Erdmann^{98,99,100,101}; Michael R Erdos⁴⁹; Johan G Eriksson^{102,103,104,105,106}; Tõnu Esko^{3,95,107}; Karol Estrada^{7,90,108}; David M Evans¹⁰⁹; Ulf de Faire¹¹⁰; Tove Fall¹¹¹; Martin Farrall¹¹²; Mary F Feitosa⁵²; Marco M Ferrario¹¹³; Teresa Ferreira⁸⁶; Jean Ferrières¹¹⁴; Krista Fischer³; Eva Fisher⁴⁵; Gerry Fowkes⁴⁷; Caroline S Fox¹¹⁵; Lude Franke^{60,116}; Paul W Franks^{117,118,119}; Ross M Fraser⁴⁷; Francesca Frau⁷⁸; Timothy Frayling⁵; Nelson B Freimer¹²⁰; Philippe Froguel^{48,56,57,121}; Mao Fu¹²²; Stefan Gaget^{56,57}; Andrea Ganna¹¹¹; Pablo V Gejman^{123,124}; Davide Gentilini⁴³; Eco JC Geus⁵¹; Christian Gieger⁴; Bruna Gigante¹¹⁰; Anette P Gjesing¹²⁵; Nicole L Glazer^{126,127}; Michael E Goddard^{128,129}; Anuj Goel¹¹²; Harald Grallert^{130,131,132}; Jürgen Gräßler¹³³; Henrik Grönberg¹¹¹; Leif C Groop⁶; Christopher J Groves³⁷; Vilmondur Gudnason^{14,15,134}; Candace Guiducci¹³⁵; Stefan Gustafsson¹¹¹; Ulf Gyllensten^{136,137}; Alistair S Hall¹³⁸; Per Hall¹¹¹; Göran Hallmans¹¹⁹; Anders Hamsten¹³⁹; Torben Hansen^{125,140}; Talin Haritunians¹⁴¹; Tamara B Harris¹⁴²; Pim van der Harst^{116,143}; Anna-Liisa Hartikainen¹⁴⁴; Neelam Hassanali³⁷; Andrew T Hattersley⁵; Aki S Havulinna¹⁴⁵; Caroline Hayward¹⁴⁶; Nancy L Heard-Costa²²; Andrew C Heath¹⁴⁷; Johannes Hebebrand¹⁴⁸; Iris M Heid^{130,149,150,151}; Martin den Heijer¹⁵²; Christian Hengstenberg^{153,154,155}; Karl-Heinz Herzig^{156,157,158}; Andrew A Hicks^{159,160,161}; Aroon Hingorani¹⁶²; Anke Hinney¹⁴⁸; Joel N Hirschhorn^{135,163,164,165}; Albert Hofman^{7,90}; Christopher C Holmes^{166,167}; Georg Homuth¹⁶⁸; Jouke-Jan Hottenga⁵¹; Kees G Hovingh²⁹; Frank B Hu^{169,170,171}; Yi-Juan Hu¹⁷²; Jennifer E Huffman¹⁴⁶; Jennie Hui^{33,34,35,75,173}; Heikki Huikuri¹⁷⁴; Steve E Humphries¹⁷⁵; Joseph Hung^{34,176}; Sarah E Hunt¹⁹; David Hunter^{169,170,171}; Kristian Hveem¹⁷⁷; Elina Hyppönen¹⁷⁸; Wilmar Igl¹³⁶; Thomas Illig^{130,131,132,179}; Erik Ingelsson¹¹¹; Carlos Iribarren^{180,181}; Bo Isomaa^{105,182}; Anne U Jackson¹; Kevin B Jacobs^{41,183}; Alan L James^{34,184}; John-Olov Jansson¹⁸⁵; Ivonne Jarick¹⁸⁶; Marjo-Riitta Jarvelin^{71,156,187,188}; Karl-Heinz Jöckel¹⁸⁹; Åsa Johansson^{136,137,190,191}; Toby Johnson^{31,40,64,192}; Jennifer Jolley²⁰; Torben Jørgensen^{193,194}; Pekka Jousilahti¹⁴⁵; Antti Jula¹⁹⁵; Anne E Justice¹⁹⁶; Marika Kaakinen^{156,187}; Mika Kähönen¹⁹⁷; Eero Kajantie^{103,198}; Stavroula Kanoni¹⁹; WH Linda Kao¹⁹⁹; Lee M Kaplan^{66,200,201}; Robert C Kaplan²⁰²; Jaakko Kaprio^{203,204,205,206}; Karen Kapur^{31,40}; Fredrik Karpe^{37,207,208}; Sekar Kathiresan^{209,210,211}; Frank Kee²¹²; Sirkka M Keinänen-Kiukaanniemi^{213,214}; Shamika Ketkar⁵²; Johannes Kettunen^{94,203}; Kay-Tee Khaw²¹⁵; Lambertus A Kiemeny^{216,217,218}; Tuomas O Kilpeläinen⁸⁰; Leena Kinnunen²¹⁹; Mika Kivimäki¹⁶²; Mika Kivimäki¹⁶²; Melanie M Van der Klauw^{60,220}; Marcus E Kleber^{221,222}; Joshua W Knowles¹⁷; Wolfgang Koenig²²³; Ivana Kolcic²²⁴; Genovefa Kolovou²²⁵; Inke R König²²⁶; Seppo Koskinen¹⁴⁵; Peter Kovacs²²⁷; Peter Kraft^{171,228}; Aldi T Kraja⁵²; Kati Kristiansson^{94,203}; Kaarel KrjutÅikov³; Heyo K Kroemer²²⁹; Jon P Krohn⁸⁶; Vjekoslav Krzelj²³⁰; Diana Kuh²³¹; Jennifer R Kulzer⁷⁶; Meena Kumari¹⁶²; Zoltán Kutalik^{31,40}; Kari Kuulasmaa²³²; Johanna Kuusisto^{233,234}; Kirsti Kvaloy¹⁷⁷; Markku Laakso^{233,234}; Jaana H Laitinen²³⁵; Timo A Lakka^{18,236}; Claudia Lamina^{130,237}; Claudia Langenberg^{80,162}; Olivier Lantieri²³⁸; G Mark Lathrop²³⁹; Lenore J Launer¹⁴²; Debbie A Lawlor⁸¹; Robert W

Lawrence⁷⁵; Irene M Leach¹⁴³; Cecile Lecoeur^{48,56,57}; Sang Hong Lee²⁴⁰; Terho Lehtimäki^{241,242}; Michael F Leitzmann¹⁴⁹; Guillaume Lettre^{58,243}; Douglas F Levinson²⁴⁴; Guo Li¹²⁷; Shengxu Li^{80,245}; Liming Liang^{171,228}; Dan-Yu Lin²⁴⁶; Lars Lind²⁴⁷; Cecilia M Lindgren^{37,86}; Jaana Lindström²¹⁹; Jianjun Liu²⁴⁸; Antonio Liuzzi²⁴⁹; Adam E Locke¹; Marja-Liisa Lokki²⁵⁰; Christina Loley^{99,226}; Ruth JF Loos^{80,251,252,253}; Mattias Lorentzon²⁵⁴; Jian'an Luan⁸⁰; Robert N Luben²¹⁵; Barbara Ludwig⁵⁴; Pamela A Madden¹⁴⁷; Reedik Mägi^{3,86}; Patrik KE Magnusson¹¹¹; Massimo Mangino²⁵⁵; Paolo Manunta²⁵⁶; Diana Marek^{31,40}; Michel Marre^{257,258}; Nicholas G Martin^{259,260}; Winfried März^{222,261}; Andrea Maschio⁸³; Iain Mathieson⁸⁶; Wendy L McArdle^{262,263}; Steven A McCarroll^{210,211,264}; Anne McCarthy²⁶⁵; Mark I McCarthy^{37,86,207,208}; Barbara McKnight¹¹; Carolina Medina-Gomez^{7,90,108}; Sarah E Medland^{259,260}; Thomas Meitinger^{266,267}; Andres Metspalu^{3,95,107}; Joyce BJ van Meurs^{7,90,108}; David Meyre^{48,57,268}; Kristian Midthjell¹⁷⁷; Evelin Mihailov^{3,95}; Lili Milani³; Josine L Min^{86,269}; Susanne Moebus¹⁸⁹; Miriam F Moffatt⁷⁴; Karen L Mohlke⁷⁶; Cliona Molony²⁷⁰; Keri L Monda^{196,271}; Grant W Montgomery^{260,272}; Vincent Mosser²⁷³; Mario A Morken⁴⁹; Andrew D Morris²⁷⁴; Andrew P Morris⁸⁶; Thomas W Mühleisen^{275,276}; Martina Müller-Nurasyid^{4,186,277,278}; Patricia B Munroe⁶⁴; Arthur W Musk^{34,173,279}; Narisu Narisu^{49,50}; Gerjan Navis²³; Benjamin M Neale²⁸⁰; Mari Nelis^{3,95,107}; James Nemeskürty²¹¹; Matt J Neville³⁷; Julius S Ngwa⁷⁷; George Nicholson^{167,281}; Markku S Nieminen²⁸²; Inger Njølstad^{283,284}; Ellen A Nohr²⁸⁵; Ilja M Nolte^{286,287}; Kari E North^{196,288}; Markus M Nöthen^{275,276}; Dale R Nyholt²⁸⁹; Jeffrey R O'Connell¹²²; Claes Ohlsson²⁵⁴; Albertine J Oldehinkel²⁹⁰; Gert-Jan van Ommen^{91,291}; Ken K Ong^{80,231}; Ben A Oostra^{90,292,293}; Willem H Ouwehand^{19,20,21,294}; Colin NA Palmer²⁷⁴; Lyle J Palmer^{34,62,63,75}; Aarno Palotie^{19,203}; Guillaume Paré²⁹⁵; Alex N Parker²⁹⁶; Lavinia Paternoster¹⁰⁹; Yudi Pawitan¹¹¹; Sonali Pechlivanis¹⁸⁹; John F Peden^{86,297,298}; Nancy L Pedersen¹¹¹; Oluf Pedersen^{125,299,300}; Niina Pellikka^{94,203}; Leena Peltonen^{19,103,203,301,302}; Brenda Penninx^{303,304,305}; Markus Perola^{3,94,203}; John RB Perry⁵; Thomas Person⁷⁰; Annette Peters^{132,306,307}; Marjolein J Peters^{7,90,108}; Irene Pichler¹⁵⁹; Kirsi H Pietiläinen^{204,308}; Carl GP Platou^{177,309}; Ozren Polasek^{224,310,311}; Anneli Pouta^{144,188}; Chris Power¹⁷⁸; Peter P Pramstaller^{159,160,161,312,313}; Michael Preuss^{100,226}; Jackie F Price⁴⁷; Inga Prokopenko^{37,86}; Michael A Province⁵²; Bruce M Psaty^{127,314,315}; Shaun Purcell^{210,301,316}; Carolin Pütter¹⁸⁹; Lu Qi^{169,170}; Thomas Quertermous¹⁷; Aparna Radhakrishnan^{19,20,294}; Olli Raitakari^{317,318,319}; Joshua C Randall^{19,86}; Rainer Rauramaa^{236,320}; Nigel W Rayner^{37,86}; Emil Rehnberg¹¹¹; Augusto Rendon^{20,21,294,321}; Martin Ridderstråle³²²; Paul M Ridker^{66,67}; Samuli Ripatti^{19,94,203}; Aila Rissanen³⁰⁸; Fernando Rivadeneira^{7,90,108}; Carlo Rivolta³¹; Neil R Robertson^{37,86}; Lynda M Rose⁶⁷; Igor Rudan^{47,230}; Timo E Saaristo^{323,324}; Hendrik Sager³²⁵; Veikko Salomaa^{145,232}; Nilesh J Samani^{326,327}; Jennifer G Sambrook^{20,294}; Alan R Sanders^{123,124}; Camilla Sandholt¹²⁵; Serena Sanna^{83,84}; Jouko Saramies³²⁸; Eric E Schadt^{329,330,331,332}; Andre Scherag¹⁸⁹; Sabine Schipf³³³; David Schlessinger³³⁴; Stefan Schreiber³³⁵; Heribert Schunkert^{98,99,100,101}; Peter EH Schwarz^{55,336}; Laura J Scott¹; Jianxin Shi⁴¹; So-Youn Shin¹⁹; Alan R Shuldiner^{122,337}; Dmitry Shungin^{117,119,338}; Stefano Signorini³³⁹; Kaisa Silander^{94,203}; Juha Sinisalo²⁸²; Boris Skrobek^{48,57}; Jan H Smit³⁰³; Albert Vernon Smith^{14,15,134}; George Davey Smith⁸¹; Harold Snieder^{60,286}; Nicole Soranzo^{19,255}; Thorkild IA Sørensen³⁴⁰; Ulla Sovio⁷¹; Timothy D Spector²⁵⁵; Elizabeth K Speliotes^{135,200,341,342}; Alena Stančáková³⁴³; Klaus Stark^{155,344}; Kari Stefansson^{345,346}; Valgerdur Steinthorsdottir³⁴⁵; Jonathan C Stephens^{20,294}; Kathleen Stirrups¹⁹; Ronald P Stolk^{60,287}; David P Strachan^{347,348}; Rona J Strawbridge¹³⁹; Heather M Stringham¹; Michael Stumvoll^{349,350,351}; Ida Surakka^{94,203}; Amy J Swift^{49,50}; Ann-Christine Syvanen³⁵²; Mari-Liis Tammesoo³; Maris Teder-Laving^{3,95,107}; Tanya M Teslovich¹; Alexander Teumer¹⁶⁸; Eirini V Theodoraki⁸²; Brian Thomson¹³⁵; Barbara Thorand³⁰⁶; Gudmar Thorleifsson³⁴⁵; Unnur Thorsteinsdottir^{345,346}; Nicholas John Timpson⁸¹; Anke Tönjes^{349,351,353}; David-Alexandre Tregouet³⁵⁴; Elena Tremoli³⁵⁵; Mieke D Trip^{29,356}; Tiinamaija Tuomi^{105,357,358}; Jaakko Tuomilehto^{219,359,360,361,362}; Jonathan Tyrer³⁶³; Manuela Uda⁸³; André G Uitterlinden^{7,90,108}; Gianluca Usala⁸³; Matti Uusitupa^{364,365}; Timo T Valle²¹⁹; Liesbeth Vandenput²⁵⁴; Vincent Vatin^{56,57}; Sailaja Vedantam^{135,163,164,165}; Femmie de Vegt²¹⁶; Sita H Vermeulen^{216,366}; Jorma Viikari³⁶⁷; Jarmo Virtamo²³²; Peter M Visscher^{240,368}; Veronique Vitart¹⁴⁶; Jana V Van Vliet-Ostaptchouk^{60,220}; Benjamin F Voight^{210,211,264}; Peter Vollenweider³⁶⁹; Claudia B Volpato¹⁵⁹; Henry Völzke^{370,371}; Gérard Waeber³⁶⁹; Lindsay L Waite²; Henri Wallaschofski^{372,373}; G Bragi Walters³⁴⁵; Zhaoming Wang^{41,183}; Nicholas J Wareham⁸⁰; Richard M Watanabe^{39,374}; Hugh Watkins¹¹²; Michael N Weedon⁵; Ryan Welch¹; Robert J

Weyant¹; Eleanor Wheeler¹⁹; Charles C White⁷⁷; H-Erich Wichmann^{130,151,375,376,377,378}; Elisabeth Widen²⁰³; Sarah H Wild⁴⁷; Gonneke Willemsen⁵¹; Cristen J Willer¹; Tom Wilsgaard²⁸³; James F Wilson⁴⁷; Sophie van Wingerden⁷; Bernhard R Winkelmann³⁷⁹; Thomas W Winkler^{149,150}; Daniel R Witte³⁸⁰; Jacqueline CM Witteman^{7,90}; Bruce HR Wolffenbuttel^{60,220}; Andrew Wong²³¹; Andrew R Wood⁵; Tsegaselassie Workalemahu^{169,170}; Alan F Wright¹⁴⁶; Jian Yang^{260,368}; John WG Yarnell³⁸¹; Lina Zgaga²²⁴; Jing Hua Zhao⁸⁰; M Carola Zillikens^{90,108}; Paavo Zitting³⁸²; Krina T Zondervan³⁸³

- 1 Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA
- 2 Hudson Alpha Institute for Biotechnology, Huntsville, Alabama 35806, USA
- 3 Estonian Genome Center, University of Tartu, Tartu 50410, Estonia
- 4 Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany
- 5 Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, EX1 2LU, UK
- 6 Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden
- 7 Department of Epidemiology, Erasmus MC, Rotterdam, 3015GE, The Netherlands
- 8 Institut Pasteur de Lille, INSERM U744, Université Lille Nord de France, F-59000 Lille, France
- 9 Telethon Institute for Child Health Research, West Perth Western Australia 6872, Australia
- 10 Centre for Child Health Research, The University of Western Australia, Australia
- 11 Departments of Biostatistics, University of Washington, Seattle, Washington 98195, USA
- 12 Collaborative Health Studies Coordinating Center, Seattle, Washington 98115, USA
- 13 Department of Epidemiology and Public Health, Faculty of Medicine, Strasbourg, France
- 14 Icelandic Heart Association, Kopavogur, Iceland
- 15 University of Iceland, Reykjavik, Iceland
- 16 Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, The Netherlands
- 17 Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
- 18 Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio Campus, Finland
- 19 Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
- 20 Department of Haematology, University of Cambridge, Cambridge CB2 0PT, UK
- 21 NIHR Cambridge Biomedical Research Centre, Cambridge, UK
- 22 Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
- 23 Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen
- 24 INSERM CESP Centre for Research in Epidemiology and Public Health U1018, Epidemiology of diabetes, obesity and chronic kidney disease over the lifecourse, 94807 Villejuif, France
- 25 University Paris Sud 11, UMRS 1018, 94807 Villejuif, France
- 26 Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds LS2 9JT, UK
- 27 University of Milan, Department of Medicine, Surgery and Dentistry, 20139 Milano, Italy
- 28 University of Cambridge Metabolic Research Labs, Institute of Metabolic Science Addenbrooke's Hospital, CB2 0QQ, Cambridge, UK
- 29 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
- 30 Regensburg University Medical Center, Innere Medizin I, 93053 Regensburg, Germany

- 31 Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland
- 32 Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, 1011 Lausanne, Switzerland
- 33 PathWest Laboratory of Western Australia, Department of Molecular Genetics, J Block, QEII Medical Centre, Nedlands, Western Australia 6009, Australia
- 34 Busselton Population Medical Research Foundation Inc., Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia
- 35 School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Western Australia 6009, Australia
- 36 Department of Surgery and Pathology, University of Western Australia, Nedlands, Australia, 6009
- 37 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, OX3 7LJ, UK
- 38 Department of Social Medicine, University of Bristol, Bristol, BS8 2PS, UK
- 39 Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
- 40 Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
- 41 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
- 42 Zentrum für Zahn-, Mund- und Kieferheilkunde, 17489 Greifswald, Germany
- 43 Molecular Biology Department, Istituto Auxologico Italiano, Milano, Italy
- 44 Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, Ulm, Germany
- 45 Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany
- 46 Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas 77030, USA
- 47 Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, Scotland
- 48 CNRS UMR8199-IBL-Institut Pasteur de Lille, F-59000 Lille, France
- 49 National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
- 50 Genome Technology Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA
- 51 Department of Biological Psychology, VU University Amsterdam, 1081 BT Amsterdam, The Netherlands
- 52 Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA
- 53 Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri 63110, USA
- 54 Department of Medicine III, University of Dresden, 01307 Dresden, Germany
- 55 Department of Medicine III, University of Dresden, Medical Faculty Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany
- 56 CNRS UMR8199-IBL-Institut Pasteur de Lille, F-59019 Lille, France
- 57 University Lille Nord de France, 59000 Lille, France
- 58 Montreal Heart Institute, Montreal, Quebec, H1T 1C8, Canada
- 59 Dipartimento di Medicina Sperimentale. Università degli Studi Milano-Bicocca, Monza, Italy
- 60 LifeLines Cohort Study, University Medical Center Groningen, University of Groningen, The Netherlands
- 61 Division of Endocrinology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
- 62 Genetic Epidemiology and Biostatistics Platform, Ontario Institute for Cancer Research. Toronto,

- Canada, M5G 1L7
- 63 Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Toronto, Canada, M5G 1X5
- 64 Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
- 65 Department of Clinical Medicine, University of Milano-Bicocca, Monza, Italy
- 66 Harvard Medical School, Boston, Massachusetts 02115, USA
- 67 Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA
- 68 Department of OB/GYN and Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA
- 69 Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, California, USA
- 70 University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas Texas 75390-8854
- 71 Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, W2 1PG, UK
- 72 British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
- 73 University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK
- 74 National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK
- 75 Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Crawley, Western Australia 6009, Australia
- 76 Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
- 77 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA
- 78 University of Milan, Department of Health Sciences, Ospedale San Paolo, 20139 Milano, Italy
- 79 Fondazione Filarete, Milano, Italy
- 80 MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
- 81 MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, Oakfield House, Bristol, BS8 2BN, UK
- 82 Department of Dietetics-Nutrition, Harokopio University, 70 El. Venizelou Str, Athens, Greece
- 83 Istituto di Neurogenetica e Neurofarmacologia del CNR, Monserrato, 09042, Cagliari, Italy
- 84 Istituto di Ricerca Genetica e Biomedica del CNR, Monserrato, 09042, Cagliari, Italy
- 85 Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva 1211, Switzerland
- 86 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
- 87 Biomedical Sciences Research Center Al. Fleming, 16672 Vari, Greece
- 88 Department of Pharmacy and Pharmacology, University of Bath, Bath, BA1 1RL, UK
- 89 Department of Internal Medicine B, Ernst-Moritz-Arndt University, 17475 Greifswald, Germany
- 90 Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA)
- 91 Center of Medical Systems Biology, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands
- 92 The London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
- 93 South Asia Network for Chronic Disease
- 94 National Institute for Health and Welfare, Department of Chronic Disease Prevention, Unit of Public Health Genomics, 00014, Helsinki, Finland

- 95 Institute of Molecular and Cell Biology, University of Tartu, Tartu 51010, Estonia
- 96 MRC-HPA Centre for Environment and Health, London W2 1PG, UK
- 97 Clinic of Cardiology, West German Heart Centre, University Hospital of Essen, University Duisburg-Essen, Germany
- 98 Nordic Center of Cardiovascular Research (NCCR), 23538 Lübeck, Germany
- 99 Universität zu Lübeck, Medizinische Klinik II, 23562 Lübeck, Germany
- 100 Universität zu Lübeck, Medizinische Klinik II, 23538 Lübeck, Germany
- 101 Deutsches Zentrum für Herz-Kreislaufforschung e. V. (DZHK), Universität zu Lübeck, 23538 Lübeck, Germany
- 102 Department of General Practice and Primary health Care, University of Helsinki, Helsinki, Finland
- 103 National Institute for Health and Welfare, 00271 Helsinki, Finland
- 104 Helsinki University Central Hospital, Unit of General Practice, 00280 Helsinki, Finland
- 105 Folkhalsan Research Centre, 00250 Helsinki, Finland
- 106 Vasa Central Hospital, 65130 Vasa, Finland
- 107 Estonian Biocenter, Tartu 51010, Estonia
- 108 Department of Internal Medicine, Erasmus MC, Rotterdam, 3015GE, The Netherlands
- 109 MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Bristol, BS8 2BN, UK
- 110 Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 111 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden
- 112 Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK
- 113 Epidemiology and Preventive Medicine Research Center, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
- 114 Department of Cardiology, Toulouse University School of Medicine, Rangueil Hospital, Toulouse, France
- 115 Division of Intramural Research, National Heart, Lung and Blood Institute, Framingham Heart Study, Framingham, Massachusetts 01702, USA
- 116 Department of Genetics, University Medical Center Groningen, University of Groningen, The Netherlands
- 117 Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
- 118 Department of Nutrition, Harvard School of Public Health, Boston, MA
- 119 Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden
- 120 Center for Neurobehavioral Genetics, University of California, Los Angeles, California 90095, USA
- 121 Department of Genomics of Common Disease, School of Public Health, Imperial College London, W12 0NN, London, UK
- 122 Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
- 123 University of Chicago, Chicago, IL
- 124 Northshore University Healthsystem, Evanston, Illinois 60201, USA
- 125 Hagedorn Research Institute, 2820 Gentofte, Denmark
- 126 Department of Medicine, University of Washington, Seattle, Washington 98101, USA
- 127 Cardiovascular Health Research Unit, University of Washington, Seattle, Washington 98101, USA
- 128 University of Melbourne, Parkville 3010, Australia
- 129 Department of Primary Industries, Melbourne, Victoria 3001, Australia
- 130 Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for

- Environmental Health, 85764 Neuherberg, Germany
- 131 Unit for Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 132 Research Unit for Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 133 Department of Medicine III, Pathobiochemistry, University of Dresden, 01307 Dresden, Germany
- 134 Department of Medicine, University of Iceland, Reykjavik, Iceland
- 135 Metabolism Initiative and Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- 136 Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, SE-75185 Uppsala, Sweden
- 137 Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
- 138 Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, UK
- 139 Atherosclerosis Research Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden
- 140 Faculty of Health Science, University of Southern Denmark, 5000 Odense, Denmark
- 141 Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
- 142 Laboratory of Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA
- 143 Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
- 144 Department of Clinical Sciences/Obstetrics and Gynecology, University of Oulu, 90014 Oulu, Finland
- 145 National Institute for Health and Welfare, Department of Chronic Disease Prevention, Chronic Disease Epidemiology and Prevention Unit, 00014, Helsinki, Finland
- 146 MRC Human Genetics Unit, Institute for Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU, Scotland, UK
- 147 Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63108, USA
- 148 Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, 45147 Essen, Germany
- 149 Regensburg University Medical Center, Department of Epidemiology and Preventive Medicine, 93053 Regensburg, Germany
- 150 Public Health and Gender Studies, Institute of Epidemiology and Preventive Medicine, Regensburg University Medical Center, Regensburg, Germany
- 151 Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 152 Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands
- 153 Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, 93053 Regensburg, Germany
- 154 Regensburg University Medical Center, Innere Medizin II, 93053 Regensburg, Germany
- 155 Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, 93053 Regensburg, Germany
- 156 Biocenter Oulu, University of Oulu, 90014 Oulu, Finland
- 157 Institute of Biomedicine, Department of Physiology, University of Oulu, 90014 Oulu, Finland
- 158 Department of Psychiatry, Kuopio University Hospital and University of Kuopio, 70210 Kuopio, Finland
- 159 Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano/Bozen, 39100, Italy. Affiliated Institute of the University of Lübeck, Lübeck, Germany.
- 160 Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano/Bozen, 39100, Italy.

- Affiliated Institute of the University of Lübeck, Lübeck, Germany.
- 161 Center for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bolzano/Bozen, 39100, Italy -
Affiliated Institute of the University of Lübeck, Lübeck, Germany.
- 162 Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place,
London WC1E 6BT, UK
- 163 Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital, Boston,
Massachusetts 02115, USA
- 164 Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
- 165 Divisions of Genetics and Endocrinology and Center for Basic and Translational Obesity Research,
Children's Hospital, Boston, Massachusetts 02115, USA
- 166 MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, OX11 0RD, UK
- 167 Department of Statistics, University of Oxford, Oxford OX1 3TG, UK
- 168 Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University
Greifswald, 17487 Greifswald, Germany
- 169 Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
- 170 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard
Medical School, Boston, Massachusetts 02115, USA
- 171 Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
- 172 Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia 30322, USA
- 173 School of Population Health, The University of Western Australia, Nedlands WA 6009, Australia
- 174 Institute of Clinical Medicine, Department of Internal Medicine, University of Oulu, 90014 Oulu,
Finland
- 175 Cardiovascular Genetics, British Heart Foundation Laboratories, Rayne Building, University College
London, London, United Kingdom
- 176 School of Medicine and Pharmacology, The University of Western Australia, Nedlands WA 6009,
Australia
- 177 HUNT Research Centre, Department of Public Health and General Practice, Norwegian University
of Science and Technology, 7600 Levanger, Norway
- 178 Centre For Paediatric Epidemiology and Biostatistics/MRC Centre of Epidemiology for Child Health,
University College of London Institute of Child Health, London, UK
- 179 Hannover Unified Biobank, Hannover Medical School, 30625 Hannover, Germany
- 180 Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA
- 181 Department of Epidemiology and Biostatistics, University of California, San Francisco, San
Francisco, California 94107, USA
- 182 Department of Social Services and Health Care, 68601 Jakobstad, Finland
- 183 Core Genotyping Facility, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702, USA
- 184 School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia
6009, Australia
- 185 Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy,
University of Gothenburg, 405 30 Gothenburg, Sweden
- 186 Institute of Medical Biometry and Epidemiology, University of Marburg, 35037 Marburg, Germany
- 187 Institute of Health Sciences, University of Oulu, 90014 Oulu, Finland
- 188 National Institute for Health and Welfare, 90101 Oulu, Finland
- 189 Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital of Essen,
University of Duisburg-Essen, Essen, Germany
- 190 Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian
University of Science and Technology (NTNU), Trondheim, N-7489, Norway
- 191 Uppsala Clinical Research Center, Uppsala university hospital, Sweden
- 192 Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of

- Medicine and Dentistry, Queen Mary, University of London, London, UK
- 193 Research Centre for Prevention and Health, Glostrup University Hospital, 2600 Glostrup, Denmark
- 194 Faculty of Health Science, University of Copenhagen, 2100 Copenhagen, Denmark
- 195 National Institute for Health and Welfare, Department of Chronic Disease Prevention, Population Studies Unit, 20720 Turku, Finland
- 196 Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, USA
- 197 Department of Clinical Physiology, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland;
- 198 Hospital for Children and Adolescents, Helsinki University Central Hospital and University of Helsinki, 00029 HUS, Finland
- 199 Department of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
- 200 Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- 201 MGH Weight Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- 202 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA
- 203 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014, Helsinki, Finland
- 204 Finnish Twin Cohort Study, Department of Public Health, University of Helsinki, 00014, Helsinki, Finland
- 205 National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Unit for Child and Adolescent Mental Health, 00271 Helsinki, Finland
- 206 National Institute for Health and Welfare, Unit for Child and Adolescent Psychiatry, Helsinki, Finland
- 207 NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, OX3 7LJ, UK
- 208 Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Old Road Headington, Oxford, OX3 7LJ, UK
- 209 Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
- 210 Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
- 211 Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
- 212 UKCRC Centre of Excellence for Public Health (NI) Queens University, Belfast
- 213 Faculty of Medicine, Institute of Health Sciences, University of Oulu, Oulu, Finland
- 214 Unit of General Practice, Oulu University Hospital, Oulu, Finland
- 215 Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 2SR, UK
- 216 Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
- 217 Department of Urology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
- 218 Comprehensive Cancer Center East, 6501 BG Nijmegen, The Netherlands
- 219 National Institute for Health and Welfare, Diabetes Prevention Unit, 00271 Helsinki, Finland
- 220 Department of Endocrinology, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands
- 221 LURIC Study nonprofit LLC, Freiburg, Germany
- 222 Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany

- 223 Department of Internal Medicine II – Cardiology, University of Ulm Medical Center, Ulm, Germany
- 224 Andrija Stampar School of Public Health, Medical School, University of Zagreb, 10000 Zagreb, Croatia
- 225 1st Cardiology Department, Onassis Cardiac Surgery Center 356, Sygrou Ave., Athens, Greece
- 226 Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, Germany
- 227 Interdisciplinary Centre for Clinical Research, University of Leipzig, 04103 Leipzig, Germany
- 228 Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
- 229 Institut für Pharmakologie, Universität Greifswald, 17487 Greifswald, Germany
- 230 Croatian Centre for Global Health, School of Medicine, University of Split, Split 21000, Croatia
- 231 MRC Unit for Lifelong Health & Ageing, London, UK
- 232 National Institute for Health and Welfare, Department of Chronic Disease Prevention, Chronic Disease Epidemiology and Prevention Unit, 00271, Helsinki, Finland
- 233 Department of Medicine, University of Kuopio and Kuopio University Hospital, 70210 Kuopio, Finland
- 234 Department of Medicine, University of Eastern Finland, Kuopio Campus and Kuopio University Hospital, 70210 Kuopio, Finland
- 235 Finnish Institute of Occupational Health, 90220 Oulu, Finland
- 236 Kuopio Research Institute of Exercise Medicine, Kuopio, Finland
- 237 Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, 6020 Innsbruck, Austria
- 238 Institut inter-regional pour la sante (IRSA), F-37521 La Riche, France.
- 239 Centre National de Genotypage, Evry, Paris 91057, France
- 240 The Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia
- 241 Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland
- 242 Department of Clinical Chemistry, Fimlab Laboratories, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland
- 243 Department of Medicine, Université de Montréal, Montreal, Quebec, H3T 1J4, Canada
- 244 Stanford University School of Medicine, Stanford, California 93405, USA
- 245 Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA
- 246 Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, USA
- 247 Department of Medical Sciences, Uppsala University, Akademiska sjukhuset, 751 85 Uppsala, Sweden
- 248 Human Genetics, Genome Institute of Singapore, Singapore 138672, Singapore
- 249 Department of Internal Medicine, Istituto Auxologico Italiano, Verbania, Italy
- 250 Transplantation Laboratory, Haartman Institute, University of Helsinki, 00014, Helsinki, Finland
- 251 The Charles Bronfman Institute of Personalized Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
- 252 Child Health and Development Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
- 253 Department of Preventive Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
- 254 Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden
- 255 Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK
- 256 Università Vita-Salute San Raffaele, Chair of Nephrology San Raffaele Scientific Institute, OU Nephrology and Dialysis, 20132 Milan, Italy

- 257 Department of Endocrinology, Diabetology and Nutrition, Bichat-Claude Bernard University Hospital, Assistance Publique des Hôpitaux de Paris, F-75018 Paris, France
- 258 Cardiovascular Genetics Research Unit, Université Henri Poincaré-Nancy 1, 54000, Nancy, France
- 259 Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia
- 260 Queensland Institute of Medical Research, Queensland 4029, Australia
- 261 Synlab Academy, Mannheim, Germany
- 262 Avon Longitudinal Study of Parents and Children (ALSPAC) Laboratory, Department of Social Medicine, University of Bristol, Bristol, BS8 2BN, UK
- 263 School of Social and Community Medicine, University of Bristol, UK
- 264 Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- 265 Division of Health, Research Board, An Bord Taighde Sláinte, Dublin, 2, Ireland
- 266 Institute of Human Genetics, Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany
- 267 Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany
- 268 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario L8S 4L8, Canada
- 269 Human Genetics, Leiden University Medical Center, Leiden 2333, The Netherlands
- 270 Merck Research Laboratories, Merck & Co., Inc., Boston, Massachusetts 02115, USA
- 271 Center for Observational Research, Amgen, Thousand Oaks, CA, 91320
- 272 Molecular Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia
- 273 Genetics Division, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA
- 274 Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School. Dundee, DD1 9SY
- 275 Institute of Human Genetics, University of Bonn, Bonn, Germany
- 276 Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
- 277 Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany
- 278 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany
- 279 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia, 6009
- 280 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114
- 281 MRC Harwell, Harwell, UK
- 282 Division of Cardiology, Cardiovascular Laboratory, Helsinki University Central Hospital, 00029 Helsinki, Finland
- 283 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
- 284 Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
- 285 Department of Public Health, Section of Epidemiology, Aarhus University, Denmark
- 286 Unit of Genetic Epidemiology and Bioinformatics, Dept of Epidemiology, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands
- 287 Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands
- 288 Carolina Center for Genome Sciences, School of Public Health, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27514, USA

- 289 Neurogenetics Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia
- 290 Interdisciplinary Center Psychopathology and Emotion Regulation, University of Groningen, University Medical Center Groningen, The Netherlands
- 291 Department of Human Genetics, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands
- 292 Department of Clinical Genetics, Erasmus MC, Rotterdam, 3015GE, The Netherlands
- 293 Centre for Medical Systems Biology & Netherlands Consortium on Healthy Aging, Leiden, the Netherlands
- 294 NHS Blood and Transplant, Cambridge Centre, Cambridge, CB2 0PT, UK
- 295 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8N3Z5, Canada
- 296 Amgen, Cambridge, Massachusetts 02139, USA
- 297 Department of Cardiovascular Medicine, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU
- 298 Illumina Inc. Cambridge
- 299 Institute of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
- 300 Faculty of Health Science, University of Aarhus, 8000 Aarhus, Denmark
- 301 The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
- 302 Department of Medical Genetics, University of Helsinki, 00014 Helsinki, Finland
- 303 Department of Psychiatry/EMGO Institute, VU University Medical Center, 1081 BT Amsterdam, The Netherlands
- 304 Department of Psychiatry, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands
- 305 Department of Psychiatry, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands
- 306 Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 307 Munich Heart Alliance, Munich, Germany
- 308 Obesity Research unit, Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland
- 309 Department of Medicine, Levanger Hospital, The Nord-Trøndelag Health Trust, 7600 Levanger, Norway
- 310 Gen-Info Ltd, 10000 Zagreb, Croatia
- 311 Faculty of Medicine, University of Split, Croatia
- 312 Department of Neurology, General Central Hospital, Bolzano, Italy
- 313 Department of Neurology, University of Lübeck, Lübeck, Germany.
- 314 Departments of Epidemiology, Medicine and Health Services, University of Washington, Seattle, Washington 98195, USA
- 315 Group Health Research Institute, Group Health, Seattle, Washington 98101, USA
- 316 Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA
- 317 Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, 20520 Turku, Finland
- 318 The Department of Clinical Physiology, Turku University Hospital, 20520 Turku, Finland
- 319 The Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, 20520 Turku, Finland
- 320 Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland
- 321 MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK
- 322 Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden
- 323 Finnish Diabetes Association, Kirjoniementie 15, 33680, Tampere, Finland

- 324 Pirkanmaa Hospital District, Tampere, Finland
- 325 Medizinische Klinik II, Universität zu Lübeck Ratzeburger Allee 160, D-23538 Lübeck, Germany
- 326 Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK
- 327 Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK
- 328 South Karelia Central Hospital, 53130 Lappeenranta, Finland
- 329 Pacific Biosciences, Menlo Park, California 94025, USA
- 330 Sage Bionetworks, Seattle, Washington 98109, USA
- 331 Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1498, New York, NY 10029-6574 USA
- 332 Institute of Genomics and Multiscale Biology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1498, New York, NY 10029-6574 USA
- 333 Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
- 334 Laboratory of Genetics, National Institute on Aging, Baltimore, Maryland 21224, USA
- 335 Institut für Klinische Molekularbiologie, Christian-Albrechts Universität, Kiel, Germany
- 336 Department of Medicine III, Prevention and Care of Diabetes, University of Dresden, 01307 Dresden, Germany
- 337 Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, Maryland 21201, USA
- 338 Department of Odontology, Umeå University, Sweden
- 339 Azienda ospedaliera di Desio e Vimercate, Milano, Italy
- 340 Institute of Preventive Medicine, Bispebjerg University Hospital, Copenhagen, and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark
- 341 Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA
- 342 Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
- 343 University of Eastern Finland and Kuopio University Hospital, 70210 Kuopio, Finland
- 344 Regensburg University Medical Center, Clinic and Policlinic for Internal Medicine II, 93053 Regensburg, Germany
- 345 deCODE Genetics, 101 Reykjavik, Iceland
- 346 Faculty of Medicine, University of Iceland, 101 Reykjavík, Iceland
- 347 Division of Community Health Sciences, St George's, University of London, London, SW17 0RE, UK
- 348 Division of Population Health Sciences and Education, St George's, University of London, London, SW17 0RE, UK
- 349 Department of Medicine, University of Leipzig, 04103 Leipzig, Germany
- 350 LIFE Study Centre, University of Leipzig, Leipzig, Germany
- 351 University of Leipzig, IFB Adiposity Diseases, Leipzig, Germany
- 352 Uppsala University / Dept. of Medical Sciences, Molecular Medicine, 751 85 Uppsala, Sweden
- 353 Coordination Centre for Clinical Trials, University of Leipzig, Härtelstr. 16-18, 04103 Leipzig, Germany
- 354 INSERM UMR_S 937, ICAN Institute, Pierre et Marie Curie Medical School, Paris 75013, France
- 355 Department of Pharmacological Sciences, University of Milan, Monzino Cardiology Center, IRCCS, Milan, Italy
- 356 Heart Failure Research Centre, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, the Netherlands
- 357 Department of Medicine, Helsinki University Central Hospital, 00290 Helsinki, Finland
- 358 Research Program of Molecular Medicine, University of Helsinki, 00014 Helsinki, Finland

- 359 Hjelt Institute, Department of Public Health, University of Helsinki, 00014 Helsinki, Finland
- 360 South Ostrobothnia Central Hospital, 60220 Seinäjoki, Finland
- 361 Red RECAVA Grupo RD06/0014/0015, Hospital Universitario La Paz, 28046 Madrid, Spain
- 362 Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria
- 363 Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK
- 364 Department of Public Health and Clinical Nutrition, University of Eastern Finland, Finland
- 365 Research Unit, Kuopio University Hospital, Kuopio, Finland
- 366 Department of Human Genetics, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
- 367 Department of Medicine, University of Turku and Turku University Hospital, 20520 Turku, Finland
- 368 Queensland Statistical Genetics Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia
- 369 Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, 1011 Lausanne, Switzerland
- 370 Institut für Community Medicine, 17489 Greifswald, Germany
- 371 Institute for Community Medicine, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany
- 372 Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Greifswald, 17475 Greifswald, Germany
- 373 Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
- 374 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
- 375 Klinikum Grosshadern, 81377 Munich, Germany
- 376 Ludwig-Maximilians-Universität, Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, 81377 Munich, Germany
- 377 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, and Klinikum Grosshadern, Munich, Germany
- 378 Klinikum Grosshadern, Munich, Germany
- 379 Cardiology Group, Frankfurt-Sachsenhausen, Germany
- 380 Steno Diabetes Center, 2820 Gentofte, Denmark
- 381 Centre for Public Health, Queen's University, Belfast, UK
- 382 Department of Psychiatries, Lapland Central Hospital, 96101 Rovaniemi, Finland
- 383 Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human Genetics, OX3 7BN, Oxford